Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)

China · Delayed Price · Currency is CNY

22.90

-1.16 (-4.82%)

At close: Nov 6, 2026

Market Cap	10.55B
Revenue (ttm)	175.37M +1,064.8%
Net Income	-450.41M
EPS	-1.12
Shares Out	460.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,234,818
Open	23.59
Previous Close	24.06
Day's Range	22.75 - 24.40
52-Week Range	19.84 - 52.52
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHA:688806

Zhuhai Trinomab Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, and commercializes therapeutics for infectious diseases and pain-related or autoimmune disorders. The company’s product includes Siltartoxatug Injection (TNM002), a recombinant anti-tetanus toxin monoclonal antibody that neutralizes the toxic effects that target the human neural system. The company was founded in 2015 and is based in Zhuhai, China. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2015

Employees 876

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688806

Full Company Profile

Financial Performance

In 2025, SHA:688806's revenue was 51.22 million, an increase of 240.23% compared to the previous year's 15.06 million. Losses were -601.32 million, 16.8% more than in 2024.

Financial Statements